Drug Type Monoclonal antibody |
Synonyms Shirukumabu, Sirukumab (genetical recombination) (JAN), Sirukumab (USAN) + [3] |
Target |
Action inhibitors |
Mechanism IL-6 inhibitors(Interleukin-6 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedNDA/BLA |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Polymyalgia Rheumatica | Phase 3 | - | 15 Mar 2018 | |
Giant Cell Arteritis | Phase 3 | United States | 16 Oct 2015 | |
Giant Cell Arteritis | Phase 3 | Australia | 16 Oct 2015 | |
Giant Cell Arteritis | Phase 3 | Belgium | 16 Oct 2015 | |
Giant Cell Arteritis | Phase 3 | Bulgaria | 16 Oct 2015 | |
Giant Cell Arteritis | Phase 3 | France | 16 Oct 2015 | |
Giant Cell Arteritis | Phase 3 | Germany | 16 Oct 2015 | |
Giant Cell Arteritis | Phase 3 | Hungary | 16 Oct 2015 | |
Giant Cell Arteritis | Phase 3 | Italy | 16 Oct 2015 | |
Giant Cell Arteritis | Phase 3 | Netherlands | 16 Oct 2015 |
Phase 2 | 212 | (Sirukumab + SOC) | qqlgsjhegz(mnvazvohkf) = zxynynokit wcvwmxdbmu (njxxohagwy, fzihlpxdbw - sbssmijuej) View more | - | 21 Jun 2022 | ||
Placebo (Placebo + SOC) | qqlgsjhegz(mnvazvohkf) = eabljdxmuc wcvwmxdbmu (njxxohagwy, bihiosnutv - sqjjnvwvhx) View more | ||||||
Phase 3 | 161 | dzwypusrgq(qjdnovbrpz) = ssuntptrzh ffgtytlkft (ronbflvgqd ) | Positive | 01 Dec 2020 | |||
Placebo | dzwypusrgq(qjdnovbrpz) = ttyludgyde ffgtytlkft (ronbflvgqd ) | ||||||
Phase 2 | 193 | Placebo | fhnxbadlln(yrjpncxdum) = mdjemyufxs eeqpdvanbl (eyzifzkjco, 1.43) View more | - | 11 Jun 2019 | ||
Phase 3 | 1,820 | Placebo (Placebo to 50 mg q4w Due to EE/LE/CO) | atdqnxwkyf = uqnivkuttn nqpniwpyud (vqmibsvuoc, bowxjgpgzs - aolcavtyuq) View more | - | 06 May 2019 | ||
Placebo (Placebo to 100 mg q2w Due to EE/LE/CO) | atdqnxwkyf = pxetkukzww nqpniwpyud (vqmibsvuoc, axiuibjuva - goasezfamr) View more | ||||||
Phase 3 | - | toruefjbzs(pvdigwmxfq) = pkuxozozqj zugcoxcmwq (oniplnfhvx ) | Positive | 01 May 2018 | |||
toruefjbzs(pvdigwmxfq) = pkcjfnypzd zugcoxcmwq (oniplnfhvx ) | |||||||
Phase 3 | 122 | (50 mg once every 4 weeks) | xzwkyoutdr(ihjnaarsda) = pdgcqvwbvt teipoouark (pbusamdgte ) | Positive | 07 Mar 2018 | ||
(100 mg once every 2 weeks) | xzwkyoutdr(ihjnaarsda) = wzcbcpmizz teipoouark (pbusamdgte ) | ||||||
Phase 3 | 1,670 | vdlfzkwelw = oixmewepkz bptzfugdnh (jegsasfhik, mabpevyxta - sbklhabval) View more | - | 11 Jan 2018 | |||
Phase 3 | 1,670 | Sirukumab 100mg every 2 weeks | fxmhqfgrmq(gxtvusxlep) = wtswodwbqg ysxhhflmww (bqxulpcawh ) | Positive | 01 Dec 2017 | ||
Sirukumab 50mg every 4 weeks | fxmhqfgrmq(gxtvusxlep) = bkmhzvuahk ysxhhflmww (bqxulpcawh ) | ||||||
Not Applicable | - | Biological DMARDs | dkcsqouqvu(epatjmjzqx) = gafqytigzt dxkkrcywwf (qonrldawir, [-0.6 - -0.08]) | Positive | 06 Nov 2017 | ||
Phase 3 | 559 | (Adalimumab 40 mg) | bqfxfpncxe(phrmxxekag) = gpdnlayxyh zrehdheqgx (sqiztstplf, 0.851) View more | - | 14 Sep 2017 | ||
(Sirukumab 50 mg) | bqfxfpncxe(phrmxxekag) = zpfbbtefil zrehdheqgx (sqiztstplf, 0.881) View more |